

## Special Issue

# From Pathogenesis to Therapies: Innovations in Kidney Disease

### Message from the Guest Editors

We warmly invite you and your colleagues to contribute original research articles or comprehensive reviews to this Special Issue. Your work will strengthen the journal and accelerate advances in nephrology. Acute kidney injury is characterized by high mortality and incidence rates. In the local renal niche, macrophages undergo differentiation into multiple phenotypes and modify the microenvironment by means of paracrine signaling, thus playing vital roles in mediating renal damage, inflammatory responses, repair processes, and fibrosis. During disease development, it remains unclear how pro-inflammatory and pro-fibrosis macrophages coexist and which signaling cues drive their transition from a repair-promoting to a profibrotic phenotype. Therefore, identifying novel and specific targets (such as key regulatory factors, abnormally activated signaling molecules, or specific cell subpopulations) is of great significance for developing drugs that block renal fibrosis and delay or even reverse renal injury. We welcome submissions that illuminate any facet of this pathway, from mechanistic studies to therapeutic discovery. We look forward to your contributions.

---

### Guest Editors

Dr. Tao Qiu

Dr. Jiefu Zhu

Dr. Chenglin Wu

---

### Deadline for manuscript submissions

30 April 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/251266](https://mdpi.com/si/251266)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).